Tempus AI (NASDAQ:TEM) CEO Eric Lefkofsky Sells 16,829 Shares

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 16,829 shares of the stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $65.54, for a total transaction of $1,102,972.66. Following the completion of the transaction, the chief executive officer directly owned 2,003,213 shares of the company’s stock, valued at $131,290,580.02. This trade represents a 0.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Tempus AI Price Performance

Shares of Tempus AI stock traded down $3.40 during midday trading on Thursday, hitting $65.69. 7,149,431 shares of the company traded hands, compared to its average volume of 6,352,496. The firm’s fifty day moving average price is $83.96 and its 200-day moving average price is $71.87. The stock has a market cap of $11.69 billion, a price-to-earnings ratio of -55.20 and a beta of 4.86. Tempus AI, Inc. has a 12 month low of $31.36 and a 12 month high of $104.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 3.12 and a current ratio of 3.28.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. The firm had revenue of $334.21 million for the quarter, compared to analyst estimates of $328.89 million. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The company’s quarterly revenue was up 84.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.46) earnings per share. Tempus AI has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Tempus AI, Inc. will post -6.15 earnings per share for the current year.

Institutional Investors Weigh In On Tempus AI

Several large investors have recently modified their holdings of TEM. EMC Capital Management acquired a new position in Tempus AI in the third quarter valued at $297,000. Sunbelt Securities Inc. acquired a new stake in Tempus AI during the 3rd quarter worth about $52,000. Captrust Financial Advisors raised its position in shares of Tempus AI by 24.8% in the 3rd quarter. Captrust Financial Advisors now owns 135,066 shares of the company’s stock worth $10,901,000 after acquiring an additional 26,853 shares in the last quarter. Danske Bank A S bought a new position in shares of Tempus AI in the 3rd quarter worth about $48,000. Finally, Advisory Services Network LLC acquired a new position in shares of Tempus AI in the 3rd quarter valued at about $256,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TEM has been the topic of several recent research reports. Piper Sandler cut their price objective on Tempus AI from $105.00 to $80.00 and set a “neutral” rating on the stock in a report on Tuesday, November 11th. Canaccord Genuity Group cut their price target on Tempus AI from $110.00 to $95.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Guggenheim upped their price objective on Tempus AI from $80.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, September 26th. HC Wainwright dropped their price objective on shares of Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a report on Friday, November 7th. Finally, TD Cowen downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and set a $88.00 target price on the stock. in a research report on Tuesday, October 21st. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $80.00.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.